Kristin Peck - Zoetis President

ZTS -- USA Stock  

Fiscal Quarter End: December 31, 2019  

  President
Ms. Kristin C. Peck is Executive Vice President and Group President, U.S. Operations, Business Development and Strategy of the Company. Ms. Peck has served as our Executive Vice President and Group President, U.S. Operations, Business Development and Strategy since March 2018, having previously served as our Executive Vice President and President, U.S. Operations from May 2015 to February 2018. From October 2012 through April 2015, she served as our Executive Vice President and Group President. Ms. Peck joined Pfizer in 2004 and held various positions, including Executive Vice President, Worldwide Business Development and Innovation Senior Vice President, Worldwide Business Development, Strategy and Innovation Vice President, Strategic Planning Chief of Staff to the Vice Chairman and Senior Director, Strategic Planning. Ms. Peck also served as a member of Pfizers Executive Leadership Team.
Age: 46  President Since 2018      
973 822-7000  www.zoetis.com
Peck holds a Bachelor degree from Georgetown University and a MBA from Columbia Business School.

Kristin Peck Latest Insider Activity

Management Efficiency

The company has Return on Asset of 11.71 % which means that on every $100 spent on asset it made $11.71 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 60.93 % implying that it generated $60.93 on every 100 dollars invested.
The company has 6.66 B in debt with debt to equity (D/E) ratio of 248.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.3 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Scott JamisonPerrigo Company Plc
2011
Thomas FarringtonPerrigo Company Plc
2015
J RamachandranDr Reddys Laboratories Ltd
2016
James DillardPerrigo Company Plc
2019
Michael AbermanRegeneron Pharmaceuticals
2015
Peter PowchikRegeneron Pharmaceuticals
2006
Marion McCourtRegeneron Pharmaceuticals
2018
Daniel PlewRegeneron Pharmaceuticals
2016
Cartikeya ReddyDr Reddys Laboratories Ltd
2016
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
George YancopoulosRegeneron Pharmaceuticals
2016
Saumen ChakrabortyDr Reddys Laboratories Ltd
2018
Paul WeningerPerrigo Company Plc
2015
Ganadhish KamatDr Reddys Laboratories Ltd
2016
Marc CouckePerrigo Company Plc
N/A
Ronald JanishPerrigo Company Plc
2015
Charles WagnerVertex Pharmaceuticals Incorpor
2019
Kimberly WhiteVertex Pharmaceuticals Incorpor
2018
John WesolowskiPerrigo Company Plc
2016
Jay MarkowitzRegeneron Pharmaceuticals
2017

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Current Sentiment - ZTS

Zoetis Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Zoetis. What is your take regarding investing in Zoetis? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased few shares of
few hours ago
Traded for 182.01
Purchased few shares of
few hours ago
Traded for 1345.02
Purchased over 40 shares of
few hours ago
Traded for 64.33
See also Your Current Watchlist. Please also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Search macroaxis.com